One reason for this drawback is that, for most cancer patients, the PD-1/PD-L1 checkpoint is not the sole factor limiting antitumor immune responses [21], and blocking this pathway alone is often insufficient to regenerate an effective antitumor immune response [22]. This evidence concerns the gene PDCD1 and cancer.